EastWest Bioscience Inc. reported earnings results for the third quarter and nine months ended April 30, 2022. For the third quarter, the company reported revenue was CAD 0.257028 million compared to CAD 0.31098 million a year ago. Net loss was CAD 0.560937 million compared to CAD 0.151866 million a year ago. Basic loss per share from continuing operations was CAD 0.01.
For the nine months, revenue was CAD 0.667364 million compared to CAD 0.935198 million a year ago. Net income was CAD 1.04 million compared to net loss of CAD 0.671454 million a year ago. Basic earnings per share from continuing operations was CAD 0.01 compared to basic loss per share from continuing operations of CAD 0.01 a year ago.